United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
United Therapeutics (NASDAQ: UTHR) reported Q2 CY2026 revenue of $783.3 million, down 1.9% year over year but 2.3% above Wall Street estimates, according to the company. GAAP EPS was $7.27, up from $6.41 and 5.9% above consensus. Analysts expect revenue to decline 20.9% over the next 12 months.
How this was made
The 30-second read
Why it matters
Q2 results were mixed: revenue declined YoY but beat estimates, EPS beat consensus, and adjusted operating margin fell YoY, while management highlighted NDA submissions in rare pulmonary diseases.
Market read
Traders get a fresh earnings datapoint (revenue, EPS, beats) alongside operating margin deterioration and a bearish 12-month revenue decline expectation, explaining why the stock sold off despite the EPS beat.
What to watch
The article cites two NDAs submitted (ralinepag tablets for PAH and nebulized Tyvaso for IPF), which could be a longer-dated growth catalyst not captured by near-term revenue decline expectations.
Background
United Therapeutics develops and commercializes medications for chronic lung diseases, focused on pulmonary hypertension treatments.
Ticker impact
United Therapeutics reported Q2 CY2026 revenue of $783.3M, down 1.9% YoY, but EPS of $7.27 beat consensus by 5.9%.
Likely choppy trading, with upside limited by the reported YoY revenue decline and guidance for further revenue/EPS softness.
The article provides a concrete earnings print (revenue, EPS, beat vs consensus) plus directionally negative operating signals (margin down YoY, revenue down YoY) and a bearish 12-month revenue decline expectation.
Market effects
Rare pulmonary disease peers may see read-across on demand durability and profitability trends in pulmonary hypertension therapies.
Primarily US large-cap biotech sentiment; limited direct regional spillover beyond healthcare earnings complex.
Modest, as the catalyst is company-specific earnings rather than a global regulatory or macro shock.
Counterpoint
The EPS beat and strong adjusted operating margin level (47.8%) could indicate cost discipline despite revenue softness, supporting a rebound if demand stabilizes.
Key entities
- companyUnited Therapeutics
NASDAQ-listed biotech reporting Q2 CY2026 revenue and EPS, plus NDA submissions for ralinepag and nebulized Tyvaso.
- executiveMartine Rothblatt
CEO and chairperson quoted on NDA submissions for PAH and IPF indications.
